Onxeo: Belinostat Abstracts for American Association for Cancer Research 2015

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, today announced that preclinical and clinical data on belinostat will be
presented at the 2015 American Association for Cancer Research (AACR) Annual
Meeting (April 18-22, 2015) in Philadelphia (Pennsylvania), USA.

Preclinical and clinical abstracts involving belinostat will be featured at the
AACR 2015. To be highlighted are especially abstracts no. 114 and 5480. Abstract
no. 114 concerns the mass balance study of 14C-belinostat in patients with
recurrent or progressive malignancy. The aim of the study is to evaluate the
excretion (mass balance) and pharmacokinetics of belinostat and to further
understand the drug’s metabolism. The study is a post-marketing requirement
study set by the US Food and Drug Administration (FDA). The study’s top-line
results show that the study was positively conducted. Abstract 5480 concerns the
clinical toxicity of belinostat, which shows that belinostat has a good safety
profile.

The studies supporting these abstracts were conducted on belinostat in different
cancer indications and have generated relevant and robust preclinical and
clinical data on the product’s profile, alone or in combination with other
chemotherapies. These first data will much help supporting and finalizing the
best development plan for belinostat and already advocate for the selection of
new promising orphan oncology indications.

The involvement of the large number of investigators in these studies
demonstrates the scientific and clinical interest on the product and is
encouraging for the future potential of clinical sites to enroll.

“Already registered and marketed in the US for the treatment of peripheral T
-cell lymphoma, belinostat has furthermore a strong potential research focus and
several potential cancer indications. The product’s development plan is being
built based on these assets and perfectly fits with our strategy to build a
robust and diversified pipeline focused on the orphan oncology”, comments Judith
Greciet, CEO of Onxeo.

Please see the abstracts, that are now available on AACR’s website
(http://www.aacr.org/ (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.aacr.org%2F&esheet=51083533&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.aacr.org%2F&index=1&md5=255bbda18e917fd7bec9988d7c2c
0 
94e)).

About the AACR

The American Association for Cancer Research
(AACR) (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aacr
. 
org%2F%3Ffdn&esheet=51083533&newsitemid=0&lan=en
-US&anchor=American+Association+for+Cancer+Research+%28AACR%29&index=2&md5=0e870
8 
8ed53fbc9d2943461ec6eaf4cb) is the first and largest cancer research
organization in the world. The Philadelphia-based nonprofit organization was
founded in 1907 by a group of 11 physicians and scientists interested in
research "to further the investigation and spread the knowledge of cancer." 

The mission of the AACR is to understand, prevent, diagnose, treat, and
cure cancer by promoting research, education, communication, and collaboration.
To that end, the AACR focuses on every facet of high-quality, innovative cancer
research.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51083533&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=3&md5=dea69caa41ceecbf9ed6ab70f451fab2)

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51083533&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=4&md5=5f3f446854423b3cd961f9a02d21b999)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51083533&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=5&md5=716249535a0099bfa2520c22eb91824f)).
Contacts :
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol / Sophie Colin – Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62